January 14, 2021
Vor Announces FDA Clearance of IND Application for VOR33
Phase 1/2a clinical trial expected to begin in first half of 2021 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vor Biopharma, a clinical-stage cell therapy…
Pharmaceuticals, Biotechnology and Life Sciences
Phase 1/2a clinical trial expected to begin in first half of 2021 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vor Biopharma, a clinical-stage cell therapy…
Significant investment from General Atlantic and The Vistria Group positions CareMetx for continued growth in supporting patient access to innovative…
Phase 1/2a clinical trial expected to begin in first half of 2021 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vor Biopharma, a clinical-stage cell therapy…
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as…
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as…
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as…
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as…
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as…
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as…
Bringing a depth of expertise in product registration, commercial & business development Tom Wiggans, former CEO of Dermira, joins as…